
多年来,科技政策的主流叙事一直聚焦于不受约束的人工智能的风险:失业、偏见和安全隐患。然而,一种反驳观点正在获得关注。麻省理工学院的著名经济学家安德鲁·麦卡菲(Andrew McAfee)认为,对长期繁荣更大的威胁不是技术进步过多,而是过少。他提出的“无需许可的创新”(permissionless innovation)概念表明,经济活力依赖于个人和小企业在无需事先获得政府批准的情况下进行实验的能力。
从实施角度来看,这会将重点从投机性的风险缓解转移到可衡量的价值创造。如果您是首席技术官或人工智能负责人,这场理论辩论具有直接的操作意义。“许可蔓延”(permission creep)的风险——即监管合规成为进入壁垒——可能会使您的竞争优势延迟12至18个月。
为了应对这一局面,请采用一个三步执行方案。
第一步:评估监管暴露与价值。在最初的两周内审计您的人工智能用例。将它们分为“高合规性”(例如,医疗保健、金融)和“低合规性”(例如,内部生产力、营销)。对于后者,优先考虑速度。不要等待出现全面的监管框架。实施轻量级的保障措施,解决特定的故障模式,而不是广泛的、未经测试的指令。
第二步:构建模块化合规层。不要将合规性硬编码到您的人工智能架构中,而是使用中间件。这使您能够随着不同司法管辖区的法规变化而更换合规模块。估计需要3-5周的冲刺来构建这些集成。这种模块化可以防止您的核心人工智能模型因监管变化而过时。
第三步:量化停滞的成本。计算延迟部署的机会成本。如果由于过度的内部风险规避导致潜在产品发布延迟六个月,请量化由此造成的收入损失。将这些数据呈现给您的董事会。这通常比抽象的安全论点更有说服力。
常见的陷阱包括对低风险应用过度设计安全检查,这会消耗预算和人才。另一个陷阱是将监管视为一个静态目标;它是动态的。您的合规策略必须像您的模型微调过程一样敏捷。
该方法的成功指标包括新人工智能功能的部署时间和合规支出占人工智能总预算的比例。对于非关键应用,目标是将合规开销保持在项目总成本的15%以下。
人工智能生态系统正朝着一个二元市场发展:高度管制的行业和开放的创新区域。将“无需许可的创新”视为战略资产而非监管负担的组织,将超越那些因恐惧而瘫痪的组织。目标不是忽视风险,而是将风险管理与创新速度脱钩。
图片:Elimende Inagella / Unsplash (https://unsplash.com/@elimendeinagella)
The energy sector's response to the Strait of Hormuz crisis offers a blueprint for AI agents to proactively build supply chain resilience.

Nokia’s procurement evolution reveals a new path. Here is a 90-day roadmap to embed AI agents into your supply chain decision-making processes.

A step‑by‑step playbook for financial institutions to launch hyper‑personalized customer experiences using AI, with timelines, resources, pitfalls, and KPIs.

Enterprises waste 60% of AI investment due to poor foundations. This 90-day playbook shows how to build scalable AI systems with measurable ROI.

评论 (2)
This framing risks conflating legitimate safety guardrails with bureaucratic red tape, a distinction that matters when dealing with critical infrastructure or personal data. While I agree that "permission creep" is a real operational hazard, ignoring the societal cost of unregulated deployment can create a false dichotomy that ultimately undermines public trust in AI governance. How do you propose balancing the need for rapid iteration with the imperative to prevent systemic harm in high-stakes sectors?
The "permission creep" timeline you cite is a critical variable often ignored when modeling ROI, but it represents a massive opportunity cost for RevOps. Regulators rarely distinguish between experimental and production-grade models, yet this distinction is exactly where we see the highest friction in our data pipelines. How are you structuring your attribution models to isolate early-stage experimental value from compliance-heavy production assets to prove that speed isn't just a nice-to-have, but a measurable revenue driver?